RAPP
NASDAQRapport Therapeutics Inc.
$36.63+0.30 (+0.83%)
News25/Ratings9
Price$36.63+0.80 (+2.25%)
01:30 PM07:45 PM
News · 26 weeks59+44%
2025-10-262026-04-19
Mix3390d
- Insider15(45%)
- SEC Filings10(30%)
- Other6(18%)
- Analyst2(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Rapport Therapeutics Inc.DEFA14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECSEC Form DEF 14A filed by Rapport Therapeutics Inc.DEF 14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
- INSIDERSEC Form 4 filed by Third Rock Ventures V, L.P.4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECRapport Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- PRRapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual MeetingClinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over baseline in weeks 13-16 New data demonstrate that RAP-219 has a half-life of approximately 22 days RAP-219 was generally well tolerated throughout treatment and follow-up periods BOSTON and SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric dis
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- ANALYSTRaymond James initiated coverage on Rapport Therapeutics with a new price targetRaymond James initiated coverage of Rapport Therapeutics with a rating of Strong Buy and set a new price target of $66.00
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- PRRapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual MeetingBOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will present results from its Phase 2a trial of RAP-219 in patients with focal onset seizures (FOS), including new data from the 8-week follow-up period, in a podium presentation at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22 in Chicago. Presentation Details Title: Efficacy and Tolerability of RAP-219, a Potential
- INSIDERSEC Form 4 filed by Gault Cheryl4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- INSIDERSEC Form 4 filed by Yeleswaram Krishnaswamy4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- SECSEC Form S-3ASR filed by Rapport Therapeutics Inc.S-3ASR - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECSEC Form S-8 filed by Rapport Therapeutics Inc.S-8 - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECSEC Form 10-K filed by Rapport Therapeutics Inc.10-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- SECRapport Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
- PRRapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateRAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) on strength of Phase 2a FOS dataPhase 2 trial in bipolar mania, development of a long-acting injectable, and other pipeline programs continued to progressEntered into a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar maniaEnded the
- INSIDERChief Operating Officer Gault Cheryl sold $58,265 worth of shares (2,014 units at $28.93), decreasing direct ownership by 1% to 169,914 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- PRRapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater ChinaPartnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights to develop and commercialize RAP-219 in Greater China across indications, including focal onset seizures and bipolar mania Rapport to receive upfront cash payment of $20 million, up to $308 million in potential development and commercial milestones and other payments, and mid-single-digit to mid-teens tiered royalties BOSTON and SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport") a clinical-stage biotechnology company dedicated to the discovery
- SECSEC Form 144 filed by Rapport Therapeutics Inc.144 - Rapport Therapeutics, Inc. (0002012593) (Subject)
- PRRapport Therapeutics to Participate in Upcoming Investor ConferencesBOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: TD Cowen 46th Annual Healthcare Conference (Boston, MA) – presentation and fireside chat on Tuesday, March 3, 2026, at 3:10-3:40 pm ET. The Citizens Life Sciences Conference (Miami, FL) – presentation on Tuesday, March 10, 2026, at 2:15 pm ET. Leerink Global Healthcare Conference (Miami, FL) –
- INSIDERChief Executive Officer Ceesay Abraham sold $320,373 worth of shares (10,916 units at $29.35), decreasing direct ownership by 1% to 556,247 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
- INSIDERChief Scientific Officer Bredt David sold $246,655 worth of shares (8,500 units at $29.02) and exercised 6,000 shares at a strike of $1.80, decreasing direct ownership by 0.63% to 393,075 units (SEC Form 4)4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)